US biopharmaceutical company Pfizer Inc (NYSE:PFE) and Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) on Thursday announced positive overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer and high-risk biochemical recurrence.
The study met a key secondary endpoint, showing a statistically significant and clinically meaningful overall survival benefit for XTANDI plus leuprolide versus placebo plus leuprolide. XTANDI monotherapy also showed a favourable trend toward improved survival, though it did not reach statistical significance.
No new safety concerns were observed, and the safety profile was consistent with previous data. Common adverse events included hot flashes and fatigue in the combination and placebo groups, and gynecomastia in the monotherapy group.
XTANDI is the first androgen receptor inhibitor-based regimen to show overall survival benefit in this patient population, reinforcing its role in advanced prostate cancer treatment. The therapy is approved in over 80 countries worldwide.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001